Publications by authors named "Maria L Naylor"

Claim this Profile
S
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.
Peter A Calabresi, Gavin Giovannoni, Hans-Peter Hartung, Robert T Naismith, Robert J Fox, Maria L Naylor

Mult Scler· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis.
Orhan Aktas, Focke Ziemssen, Tjalf Ziemssen, Alexander Klistorner, Helmut Butzkueven, Maria L Naylor

Mult Scler Relat Disord· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.
Gary Cutter, Richard A Rudick, Carl de Moor, Carol M Singh, Elizabeth Fisher, Maria L Naylor

Mult Scler J Exp Transl Clin· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study.
Yuan Zhao, Oksana Mokliatchouk, Nancy F Ramia, Maria L Naylor, Cherié L Butts

Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Jeffrey A Cohen, Robert A Bermel, Cynthia I Grossman, Carrie M Hersh, Megan Hyland, Maria L Naylor

Mult Scler· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
Marco Salvetti, Sibyl Wray, Gereon Nelles, Arman Altincatal, Achint Kumar, Maria L Naylor

Mult Scler Relat Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Scott D Newsome, Thomas F Scott, Douglas L Arnold, Arman Altincatal, Maria L Naylor

Mult Scler Relat Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach.
Sarah White, Colleen Harris, Michelle Allan, Carol Chieffe, Piet Eelen, Maria L Naylor

Neurol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Anthony T Reder, Diego Centonze, Maria L Naylor, Anjali Nagpal, Rajani Rajbhandari

CNS Drugs· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate.
Thomas F Scott, Ray Su, Kuangnan Xiong, Arman Altincatal, Carmen Castrillo-Viguera, Maria L Naylor

Ther Adv Neurol Disord· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers.
Yuan Zhao, Kun Chen, Nancy Ramia, Sangeeta Sahu, Achint Kumar, Maria L Naylor

Ther Adv Neurol Disord· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Scott D Newsome, Oksana Mokliatchouk, Carmen Castrillo-Viguera, Maria L Naylor

Mult Scler Relat Disord· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN.
Scott D Newsome, Thomas F Scott, Douglas L Arnold, Gereon Nelles, Serena Hung, Maria L Naylor

Ther Adv Neurol Disord· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis.
Douglas L Arnold, Shulian Shang, Qunming Dong, Matthias Meergans, Maria L Naylor

Ther Adv Neurol Disord· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling DNA damage-induced phosphorylation in budding yeast reveals diverse signaling networks.
Chunshui Zhou, Andrew E H Elia, Maria L Naylor, Noah Dephoure, Bryan A Ballif

Proc Natl Acad Sci U S A· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mrc1 phosphorylation in response to DNA replication stress is required for Mec1 accumulation at the stalled fork.
Maria L Naylor, Ju-mei Li, Alex J Osborn, Stephen J Elledge

Proc Natl Acad Sci U S A· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAD51-dependent break-induced replication differs in kinetics and checkpoint responses from RAD51-mediated gene conversion.
Anna Malkova, Maria L Naylor, Miyuki Yamaguchi, Grzegorz Ira, James E Haber

Mol Cell Biol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential role of limiting telomeres in the pathogenesis of Werner syndrome.
Sandy Chang, Asha S Multani, Noelia G Cabrera, Maria L Naylor, Purnima Laud

Nat Genet· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression.
Sandy Chang, Christine M Khoo, Maria L Naylor, Richard S Maser, Ronald A DePinho

Genes Dev· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis